Evidence map›Paper›PMID 40172573›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2025

The Breast Tumor Immune Microenvironment of DNA Double-Strand Break Repair Pathogenic Variant Carriers Is Enriched with Tumor-Associated Macrophages.

Rebecca L Kelly, Yuxi Liu, Alexandra R Harris, Cheng Peng, Yujing J Heng, Gabrielle M Baker, Daniel G Stover, Rulla M Tamimi, Peter Kraft

Abstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rebecca L KellyCancer Prevention Fellowship Program, National Cancer Institute, Rockville, Maryland.ORCID 0009-0009-4378-737X
Yuxi LiuDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.ORCID 0000-0003-2484-151X
Alexandra R HarrisCancer Prevention Fellowship Program, National Cancer Institute, Rockville, Maryland.ORCID 0000-0002-1049-3131
Cheng PengChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0002-0220-5128
Yujing J HengDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-8930-817X
Gabrielle M BakerDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-9213-0317
Daniel G StoverDivision of Medical Oncology, Stefanie Spielman Comprehensive Breast Center, Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0001-9003-8165
Rulla M TamimiDepartment of Population Health Sciences, Weill Cornell Medicine, New York, New York.ORCID 0000-0003-2306-8668
Peter KraftDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.ORCID 0000-0002-4472-8103

Funding

Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, TAMIMI, RULLA M · 2000 to 2019
$77.8M
Risk Factors for Breast Cancer in Younger NursesR01CA050385 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ELIASSEN, A. HEATHER, WILLETT, WALTER C. · 1989 to 2019
$32.3M
Life Course Cancer Epidemiology Cohort in WomenU01CA176726 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI ELIASSEN, A. HEATHER, WILLETT, WALTER C. · 2018 to 2025
$22.4M
Long Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3M
Premonopausal Hormone Levels and Risk of Breast CancerR01CA067262 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HANKINSON, SUSAN E · 2002 to 2011
$11.9M
BIOCHEMICAL MARKERS IN THE NURSES'HEALTH STUDY COHORTR01CA049449 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI HANKINSON, SUSAN E · 1989 to 2008
$11.3M
Epidemiologic StudiesU19CA148065 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI AHSAN, HABIBUL, BRUGGE, JOAN SIEFERT · 2010 to 2014
$10.6M
BIOCHEMICAL MARKERS IN THE NURSES HEALTH STUDY COHORTU01CA049449 · NCI · UNIVERSITY OF MASSACHUSETTS AMHERST · PI HANKINSON, SUSAN E · 1995 to 2013
$5.4M
Assessing the role of androgens in breast cancer riskR01CA166666 · NCI · UNIVERSITY OF MASSACHUSETTS AMHERST · PI HANKINSON, SUSAN E · 2012 to 2015
$1.7M
Prediagnostic exposures, germline genetics, and triple negative breast cancer mutational and immune profilesR01CA260352 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI KRAFT, PETER, TAMIMI, RULLA M · 2021 to 2022
$1.3M
Division of Cancer Prevention, National Cancer Institute (DCP, NCI)National Cancer Institute (NCI) P01CA087969National Cancer Institute (NCI) R01CA166666National Cancer Institute (NCI) R01CA260352National Cancer Institute (NCI) R01CA49449National Cancer Institute (NCI) R01CA50385National Cancer Institute (NCI) R01CA67262National Cancer Institute (NCI) U01CA176726National Cancer Institute (NCI) U19CA148065National Cancer Institute (NCI) UM1CA186107NCI NIH HHS P01 CA087969NCI NIH HHS R01 CA049449NCI NIH HHS R01 CA050385NCI NIH HHS R01 CA067262NCI NIH HHS R01 CA166666NCI NIH HHS R01 CA260352NCI NIH HHS U01 CA049449NCI NIH HHS U01 CA176726NCI NIH HHS U19 CA148065NCI NIH HHS UM1 CA186107
6 · The paper itself

Abstract

backgroundApproximately 5% of patients with breast cancer have a rare pathogenic germline genetic variant that is associated with increased breast cancer risk. Mutations in more than 12 genes have been associated with hereditary breast cancer risk, many of which are involved in genome stability pathways, including DNA double-strand break (DSB) repair. We hypothesized that carriers of DSB repair-related pathogenic variants (PV) may have a distinct tumor immune environment that differs from that of noncarriers.

methodsWe utilized tumor transcriptome data from 559 participants with invasive breast cancer from the Nurses' Health Studies and Nurses' Health Studies II to infer immune-related gene expression signatures and immune cell abundance.

resultsThirty-three (5.9%) individuals had germline DSB repair-related PVs in one or more of the following genes: ATM, BARD1, BLM, BRCA1, BRCA2, BRIP1, CHEK2, FANCC, FANCM, NBN, PALB2, RAD50, RAD51C, and/or RECQL. In covariate-adjusted analyses, DSB repair-related PV carrier status was positively associated with both a STAT1 signature (standardized β = 0.59; P = 3.5 × 10-3) and inferred M1 macrophage infiltration (standardized β = 0.56; P = 1.4 × 10-3). Furthermore, these immune features correlated with other features related to tumor IFN response signaling, suggesting that this enrichment is occurring in an inflammatory context.

conclusionsThese results indicate that breast tumors of DSB repair-related PV carriers have distinct immune features, which may have therapeutic implications in this high-risk population. IMPACT: These results support further characterization of macrophage characteristics and abundance in the breast tumor microenvironment of DSB repair-related PV carriers.

Indexed as

Breast NeoplasmsDNA Breaks, Double-StrandedDNA RepairTumor-Associated MacrophagesTumor MicroenvironmentAdultFemaleGenetic Predisposition to DiseaseGerm-Line MutationHumansMiddle Aged

Identifiers

PMID40172573
PMCPMC12374719

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.